GPR55 and encephalopathy, progressive, early-onset, with brain edema and/or leukoencephalopathy: Our results suggest that GPR55 antagonism may not be a suitable anticonvulsant target for Dravet syndrome drug development programs, although future research is needed to provide more definitive conclusions.